Immunome, Inc. (IMNM) Sets Sights on $1B Opportunity amid Pipeline Development [Yahoo! Finance]
Immunome, Inc. (IMNM)
Company Research
Source: Yahoo! Finance
Clay Siegall reiterated heightened focus on building an oncology-focused pipeline centered on cell-surface-targeting agents and small molecules. Immunome, Inc. (IMNM) Sets Sights on $1B Opportunity amid Pipeline Development David Smart/Shutterstock.com The ultimate goal is to develop a targeted oncology platform for small molecules that can overcome resistance and enable bystander activity. The remarks come on the company delivering top-line Phase 3 results for Varegacestat in desmoid tumors. The company is in the process of filing a New Drug Application as it sets its sights on a $1 billion market opportunity, targeting the over 3,000 patients treated annually. Immunome also plans to submit three additional INDs this year targeting solid tumor programs. The push comes as the company's radioligand therapy, which delivers radiation directly to tumors, receives FDA clearance. It is poised to start a clinical trial soon. Immunome, Inc. (NASDAQ:IMNM) is a clinical-stage biotechn
Show less
Read more
Impact Snapshot
Event Time:
IMNM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMNM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMNM alerts
High impacting Immunome, Inc. news events
Weekly update
A roundup of the hottest topics
IMNM
News
- Immunome's Chief Scientist Trimmed His Stake. A Planned FDA Submission Tells You More [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Immunome's Chief Scientist Trimmed His Stake. A Planned FDA Submission Tells You More [Yahoo! Finance]Yahoo! Finance
- Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Immunome: Upcoming NDA, Valuation, And Investment Case [Seeking Alpha]Seeking Alpha
- Immunome (IMNM) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=IMNM&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "hold" to "selMarketBeat
IMNM
Earnings
- 8/6/25 - Beat
IMNM
Sec Filings
- 4/3/26 - Form 4
- 4/3/26 - Form 4
- 4/3/26 - Form 144/A
- IMNM's page on the SEC website